Morgan Stanley Lowers Compass Pathways Stock Price Target Amid TRD Progress
Published on · Source: investing.com
AI Summary
Summarized by AI from the source belowMorgan Stanley has reduced its stock price target for Compass Pathways to $X from $Y, citing progress in development for treatments related to TRD (treatment-resistant depression). The update reflects changing expectations related to the company's clinical trials and market potential. This adjustment may impact investor sentiment and trading volumes for Compass Pathways shares.
Informational only, not financial advice. Content is AI-generated and may contain errors. How this works.
About Morgan Stanley (MS)
Morgan Stanley is a leading global investment bank and wealth manager.
The Financials sector covers banks, insurers and capital-markets firms at the center of the economy.
Earlier MS news
- Palantir Posts $11.2 Billion Revenue Backlog and 61% Growth Forecast
- Morgan Stanley Upgrades Insurance Stock on Tesla Partnership Potential
- Nvidia Surpasses Micron as Morgan Stanley's Preferred Chip Stock Choice
Get the weekly market brief
One email every Monday: what moved, why, and what to watch. Free, unsubscribe anytime.
